HER-2/neu receptor gene status in endometrial carcinomas: A tissue microarray study

Histopathology

Volumn 56, Issue 2, 2010, Pages 269-273

  Xu, Mina ^a   Schwartz, Peter ^a   Rutherford, Thomas ^a   Azodi, Mazu ^a   Santin, Alexandro ^a   Silasi, Dan ^a   Martel, Martiza ^a   Hui, Pei ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; MESSENGER RNA; TRASTUZUMAB;

CONTROLLED STUDY; ENDOMETRIUM CARCINOMA; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LETTER; MAJOR CLINICAL STUDY; ONCOGENE NEU; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TISSUE MICROARRAY;

AGED; AGED, 80 AND OVER; ENDOMETRIAL NEOPLASMS; FEMALE; GENES, ERBB-2; HUMANS; RECEPTOR, ERBB-2;

EID: 73449083076     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2009.03464.x     Document Type: Letter

References (13)

1. Santin AD, Belone S, Van Stedum S et al. Determination of HER2/neu status in uterine serous papillary carcinoma: comparative analysis of immunohistochemistry and fluorescence in situ hybridization. Gynecol. Oncol. 2005 98 24 30.
2. Prat J, Oliva E, Lerma E et al. Uterine papillary serous adenocarcinoma: a 10-case study of p53 and c-erb-2 expression and DNA content. Cancer 1994 74 1778 1783.
3. Khalifa MA, Mannel RS, Haraway SD et al. Expression of EGFR, HER-2/neu, P53, and PCNA in endometrioid, serous papillary, and clear cell endometrial adenocarcinomas. Gynecol. Oncol. 1994 53 84 92.
4. Peiro G, Mayr D, Hillemanns R et al. Analysis of HER-2/neu amplification in endometrial carcinoma by chromogenic in situ hybridization: correlation with fluorescence in situ hybridization HER-2/neu, p53 and KI-67 protein expression and outcome. Mod. Pathol. 2004 17 227 287.
5. Singh P, Smith CL, Cheertham G et al. Serous carcinoma of the uterus - determination of HER-2/neu status using immunohistochemistry, chromogenic in situ hybridization, and quantitative polymerase chain reaction techniques: its significance and clinical correlation. Int. J. Gynecol. Cancer 2008 18 1344 1351.
6. Diaz-Montes TP, Ji H, Smith AE et al. Clinical significance of HER-2/neu overexpression in uterine serous carcinoma. Gynecol. Oncol. 2006 100 139 144.
7. Grushko TA, Filiaci VL, Mundt AJ et al. Gynecologic Oncology Group. An exploratory analysis of HER-2 amplification and overexpression in advanced endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol. Oncol. 2008 108 3 9.
8. Santin AD, Bellone S, Roman JJ et al. Trastuzumab treatment in patients with advanced or recurrent endometrial carcinoma overexpressing Her2/neu. Int. J. Gynaecol. Obstet. 2008 102 128 131.
9. Villella JA, Cohen S, Smith DH et al. HER-2/neu overexpression in uterine papillary serous cancers and its possible therapeutic implications. Int. J. Gynecol. Cancer 2006 16 1897 1902.
10. Berchuck A, Rodriguez G, Kineny RB et al. Overexpression of HER-2/neu in endometrial cancer is associated with advanced stage disease. Am. J. Obstet. Gynecol. 1991 164 15 21.
11. Coronado PJ, Vidart JA, Lopez-Asenjo JA et al. p53 overexpression predicts endometrial carcinoma recurrence better than HER-2/neu overexpression. Eur. J. Obstet. Gynecol. Reprod. Biol. 2001 98 103 108.
12. Slomovitz BM, Broaddus RR, Burke TW et al. HER-2/neu overexpression and amplification in uterine papillary serous carcinoma. J. Clin. Oncol. 2004 22 3126 3132.
13. Odicino FE, Bignotti E, Rossi E et al. HER-2/neu overexpression and amplification in uterine serous papillary carcinoma: comparative analysis of immunohistochemistry, real-time reverse transcription-polymerase chain reaction, and fluorescence in situ hybridization. Int. J. Gynecol. Cancer 2008 18 14 21.